CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation
Our findings suggest that CU06-1004 inhibits inflammation-induced tumorigenesis by modulating the inflammatory response in the colon. Consequently, CU06-1004 could represent a promising therapeutic candidate for the prevention of colorectal cancer through modulation of inflammation.
Authors
- Sang‐Jun Ha (ORCID: https://orcid.org/0000-0002-1192-6031)
- Dongyeop Kim (ORCID: https://orcid.org/0000-0002-6185-9463)
- Yeomyeong Kim
- Ye-Seul Kim (ORCID: https://orcid.org/0000-0002-1542-2367)
- Cho-Rong Bae
- Minyoung Noh (ORCID: https://orcid.org/0000-0002-0750-1460)
- Young‐Guen Kwon (ORCID: https://orcid.org/0000-0002-1534-2455)
- Haiying Zhang (ORCID: https://orcid.org/0000-0001-6431-3637)
Institutions
- Yonsei University (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fphar.2025.1684870
- Citations
- 2
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea